Clinical trial · Observational
Safety and Effectiveness of Nivolumab in Recurring Kidney Cancer Participants
Efficacy and Safety of Nivolumab in Metastatic Renal Cell Cancer Patients - Japanese Real-World Data Through Clinical Chart Review
NCT03568435CI-TRIAL-00061570completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A non-interventional, medical record review of clinical data collected from Japanese participants with recurring kidney cancer
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Kidney Cancer | Malignant Kidney Neoplasm | CURATED_EXACT | 0.92 |
| Renal Cancer | Kidney Neoplasm | PROBABILISTIC | 0.70 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Non-Interventional | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Participants with metastatic RCC taking nivolumab
- description
- Specified dose on specified day
- interventionNames
- Other: Non-Interventional
Primary outcomes (14)
- measure
- Overall survival status
- timeFrame
- 6 months
- measure
- Overall survival status
- timeFrame
- 36 months
- measure
- Best overall response
- timeFrame
- 6 months
- measure
- Best overall response
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * A patient with RCC with distant metastasis treated for the first time with nivolumab Exclusion Criteria: * Patients who have participated in some trials with immuno-checkpoint blockade before or after treatment with nivolumab after diagnosis with RCC Other protocol defined inclusion/exclusion criteria could apply
References
Publications (0)
Data not yet available
No reference posted for this study.